Xbiome

📍 Cambridge, United States🗓 Founded 2017👥 48 employees💰 Last funded Dec 2020
Biotechnology Research🌐 xbiome.com
Website LinkedIn
As the leading AI-based microbiome drug development company in China, Xbiome Co., Ltd. is dedicated to gut microbiome using AI techniques, and committed to the gut health of human being with medical treatments and precise and personalized management. The gut is the largest microbial ecosystem in the human body. It hosts about 100 trillion microbes – 500 – 1000 unique species, and contains 150-fold more genes than the human genome, which influence the human health systematically. Studies show that more than 50 human diseases are associated with dysbiosis of gut microbiota. Unlike the traditional paradigm of drug discovery, Xbiomes approach innovatively combines microbial technologies, artificial intelligence, bioinformatics analysis and gut microbiome technologies into a unique drug development platform, which substantially speeds up and improves the success rate of new drug development.
2
Total investors
0
Early stage
2
Mid stage
0
Late stage
2017
Founded

Investors

2 investors
All
Early stage
Mid stage
Late stage
Investor geography2 countries
United States
1
Hong Kong
1
Frequently asked questions
Who invested in Xbiome?
Xbiome has 2 investors on record on gritt.io, 2 mid-stage.
When did Xbiome last raise funding?
The most recent investment in Xbiome recorded on gritt.io was in December 2020.
When was Xbiome founded?
Xbiome was founded in 2017.
What industry is Xbiome in?
Xbiome operates in Biotechnology Research. Find similar Biotechnology Research investors on gritt.io.
Where is Xbiome based?
Xbiome is headquartered in Cambridge, United States.